Tasquinimod is an orally active anti-angiogenic drug that is currently in Phase III clinical trials for the treatment of castration resistant prostate cancer. However, the target of this drug has remained unclear. In this study we applied diverse strategies to identify the histone deacetylase HDAC4 as a target for the anti-angiogenic activity of client transcription factors, such as HIF-1α, which are bound at promoter/enhancers where epigenetic reprogramming is required for cancer cell survival and angiogenic response. Through this mechanism, tasquinimod is effective as a monotherapeutic agent against human prostate, breast, bladder, and colon tumor xenografts, where its efficacy could be further enhanced in combination with a targeted thapsigargin prodrug (G202) that selectively kills tumor endothelial cells. Together, our findings define a mechanism of action of tasquinimod and offer a perspective on how its clinical activity might be leveraged in combination with other drugs that target the tumor microenvironment.
Abstract
Tasquinimod is an orally active anti-angiogenic drug that is currently in Phase III clinical trials for the treatment of castration resistant prostate cancer. However, the target of this drug has remained unclear. In this study we applied diverse strategies to identify the histone deacetylase HDAC4 as a target for the anti-angiogenic activity of 3D-endothelial sprouting assay was performed using a minimum of 5 replicate wells per drug dose per experiment, repeated 3 independent times as described previously (11) using HUVECs [Lonza Walkersville Inc (Walkersville, MD)] with modification that 20ul of 10X concentrated DMEM/10%FCS media conditioned by confluent human primary lung fibroblasts (Lonza) diluted to 200ul of growth factor supplemented EGM-2 media (Lonza) was used instead of fibroblast co-culture.
Cancer models: The source, history, and characteristics of the normal and malignant human epithelial lines used, as well as cell culture conditions for their in vitro maintenance and the in vivo protocol for their xenografting into immune-deficient nude mice are as described previously (3, 12, 13) . All lines were mycoplasma negative using the MycoSensor PCR Assay kit (Agilent Technologies) and genetically authenticated within the last 6 months using STR profiling performed by the Johns Hopkins Genetic Resource Core Facility. In vitro growth curves were determined as described (12, 13) .
Animal studies were performed according to animal protocol MO09M434 approved by Johns Hopkins Animal Care and Use Committee. Daily orally TasQ dosing via the drinking water, tumor volume measurements, tumor blood vessel density determination, and tissue oxygenation expressed as mmHg were as described previously (3, 4) . These experiments were repeated at 3 independent times for each xenograft. Total HDAC and isotype specific HDAC enzymatic activity was assayed on a per cell basis using the appropriate substrates as described previously (14, 15 Surface plasmon resonance: SPR analysis was carried out with the Biacore 3000 system (GE Healthcare) as described previously (16) . Sensor chips, amine coupling kit, immobilization and running buffers, and regeneration solutions were as described previously (16) . Binding to Tasquinimod was determined for human full length Nterminal GST-tagged HDAC4 (Abnova cat#H00009759-P01). GST-tagged HDAC4 was immobilized onto a CM5 chip through an amine-linkage. This chip was used to determine binding of full length human N-CoR (Abcam Cat # ab82239). These experiments were repeated 3 independent times.
Computer docking modeling:
The active vs. and inactive conformations of HDAC4 were overlaid using the Ca atoms of crystal structures previous reported (17) . Protein surfaces generated and systematically examined for plausible binding pockets. The 
Gene Expression Profiling:
Normal prostate samples from organ donors (n=23) were obtained as described previously (20) . Castration resistant prostate cancer specimens (n=18) were autopsy specimens from 6 patients who died from PCa, as previously reported (21) . The use of autopsy specimens for molecular analysis was approved by the Johns Hopkins Medicine Institutional Review Boards. Gene expression profiling was performed 3 independent times according to the guidelines provided by the Agilent Whole Genome Expression Microarray system (Agilent Technologies, Santa Clara CA), using 2-color design and the results normalized to a reference sample derived from benign prostatic hyperplasia using the standard locally weighted least squares regression (LOWESS) procedure as described previously (22) . There are multiple isotypes of class I (HDAC1, 2, 3, 8), class IIa (HDAC4, 5, 7, 9) and IIb HDACs (HDAC6) (27) Within the HDAC domain, there is a zinc-bound "catalytic domain" involving AA802-950, however HDAC4 is enzymatically inactive against classic acetylated peptide substrates (14, 15) . Also within the HDAC domain is a regulatory zinc-binding domain (ZRD) (AA648-751), Figure 3A . Crystallography studies document that the ZRD has two alternative conformations (17) . When Zn To confirm these observations, HIF-1α was compared between control, HDAC4 shRNA2 knock-down, and knock down restored LNCaPs. As expected, HDAC4 knockdown decreases HIF-1α and this is reversed when HDAC4 is restored, Figure 4D signaling not only inhibits endothelial tumor angiogenesis, but also growth/survival of a variety of human organ-specific cancers (29, 30, 39, 40) . To evaluate this possibility, a series of human prostate, breast, bladder, and colon cancer xenografts were inoculated into appropriate immune-suppressed hosts and cancers allowed to reach 0.250cc before daily oral TasQ (10mg/kg/d) was initiated. As predicted, TasQ monotherapy inhibited (p< 0.05) subsequent tumor growth by a least 50% in all of these cancer types, 
combining TasQ with agents which increase tumor microenvironmental stress should enhance therapeutic efficacy. To test this prediction, TasQ was combined with G202 which is a Thapsigargin prodrug engineered to be hydrolyzed to a cytotoxin by a protease uniquely expressed by cancer associated endothelial cells in order to selectively kill tumor endothelial cells enhancing a more stressful tumor microenvironment (12) . When estrogenized female nude mice are inoculated with MCF-7 human breast cancer cells and cancers allowed to grow to a starting size of ~0.2cc before animals are given a single cycle of 2 daily IV injections of 56mg/kg of G202, cancers regress due to the death of tumor associated endothelial and cancer cells and in a subset of animals, the cancers does not regrow (12) . If such breast cancers are allowed to grow to a starting size of ~0.8cc before initiating a single 2 day cycle with G202, cancers regress by >50% followed by regrowth, Figure 7C . 
inhibitors to suppress cancer growth via reduced tumor angiogenesis (30, 33) .
Limitation with using pan-or type 1 isotype selective HDAC inhibitors, however, is that they up-regulate, instead of repress, transcription of a subset of unwanted survival genes [e.g., GRP78/BiP, Cox-2, FGF2, Slit2] (41-46). Thus, selective inhibition of HDAC4 signaling is a more optimal approach for blocking the angiogenic switch without activating unwanted survival signaling within cancer sites.
The present studies identify TasQ as such a high affinity HDAC4 selective negative allosteric modulator . Besides allosterically binding HDAC4, TasQ also binds with high affinity to the calcium binding protein, S100A9 (7, 16) . In the presence of zinc, S100A9 undergoes a conformational change becoming a ligand for the proinflammatory Toll like receptor 4 (TLR4) and TasQ binding to S100A9 inhibits this binding to TLR4 (7) . This is significant because myeloid-derived suppressor cells (MDSCs) from the bone marrow circulate in the blood and express S100A9 protein and TLR4 and S100A9 binding to TLR4 stimulates tumor infiltration of MDSCs (7, 47, 48) . 
